Lupus & antiphospholipid syndrome
Sustained glucocorticoid tapering in the phase 3 trials of anifrolumab: apost hocanalysis of the TULIP-1 and TULIP-2 trials
Authors' conclusion
Sustained glucocorticoid tapering is associated with clinical benefits.
Study context
- Population
- Patients with moderate to severe SLE receiving GC (prednisone or equivalent) 10 mg or more per day at baselineof 726 TULIP patients
- Participants
- 375 patients
- Comparison
- Sustained GC taper responders vs non-responders; anifrolumab vs placebo
- Sustained GC taper respondersn = 155
- Non-respondersn = 220reference
- Anifrolumabn = 190
- Placebon = 185reference
Methodological detailsrandomized, placebo-controlled, 52-week, phase 3
- Randomized
- Placebo-controlled
- 52-week
- Phase 3
Primary result
As reported in the abstract
Sustained GC tapering · week 52
- Sustained GC taper responders overall
- 155 (41%)
Further findings
| Outcome | Anifrolumab | Placebo |
|---|---|---|
| Sustained GC taper and reduced overall disease activity | 38% | 23% |
Responders vs non-responders: cumulative GC dose, patient-reported outcomes (PROs), blood pressure
- Responders reduced mean cumulative GC dose vs non-responders
- 32%
- Responders improved PRO scores and reduced blood pressure
Safety
- Fewer serious adverse events in sustained GC taper responders than non-responders
Original publication
Sustained glucocorticoid tapering in the phase 3 trials of anifrolumab: apost hocanalysis of the TULIP-1 and TULIP-2 trials. Rheumatology (Oxford). Published 26 August 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →